PASG vs. CRIS, ALVR, PLX, ATHA, OTLK, GRTS, JATT, ELUT, DTIL, and CGTX
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Curis (CRIS), AlloVir (ALVR), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Outlook Therapeutics (OTLK), Gritstone bio (GRTS), JATT Acquisition (JATT), Elutia (ELUT), Precision BioSciences (DTIL), and Cognition Therapeutics (CGTX). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Curis has higher revenue and earnings than Passage Bio. Curis is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
Passage Bio currently has a consensus price target of $9.00, indicating a potential upside of 581.82%. Curis has a consensus price target of $37.33, indicating a potential upside of 216.38%. Given Passage Bio's higher possible upside, equities analysts plainly believe Passage Bio is more favorable than Curis.
In the previous week, Passage Bio had 3 more articles in the media than Curis. MarketBeat recorded 17 mentions for Passage Bio and 14 mentions for Curis. Passage Bio's average media sentiment score of 0.83 beat Curis' score of 0.56 indicating that Passage Bio is being referred to more favorably in the media.
Passage Bio has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, indicating that its stock price is 259% more volatile than the S&P 500.
Passage Bio has a net margin of 0.00% compared to Curis' net margin of -486.45%. Passage Bio's return on equity of -68.53% beat Curis' return on equity.
Curis received 640 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 67.65% of users gave Curis an outperform vote while only 66.67% of users gave Passage Bio an outperform vote.
Summary
Passage Bio beats Curis on 9 of the 15 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
